학술논문
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial
Document Type
Article
Author
Moyle, G.; Pozniak, A.; Assoumou, L.; de Castro, N.; Post, F.A.; Curran, A.; Rusconi, S.; De Wit, S.; Stephan, C.; Raffi, F.; Johnson, M.; Masia, M.; Vera, J.; Jones, B.; Grove, R.; Fletcher, C.; Duffy, A.; Morris, K.; Post, F.; Winston, A.; Kegg, S.; Waters, L.; Orkin, C.; Ustianowski, A.; Reeves, I.; Leen, C.; Perry, M.; Portilla, J.; Blanco, J.L.; Montejaro, R.; Domingo, P.; Molina, J.M.; Katlama, C.; Morlat, P.; Kenyon, C.; Puoti, M.; Rizzardini, G.; Castagna, A.; Castelli, F.; Giacomelli, A.; Rockstroh, J.; Esser, S.; Hoffmann, C.; Mallon, P.
Source
In: The Lancet HIV . (The Lancet HIV, March 2024, 11(3):e156-e166)
Subject
Language
English
ISSN
23523018